The abstract is read at the publisher; the summary is JClub's.
ReSort and ANCHOR enable scalable prioritization of 87 clinically actionable tumor-associated antigens across solid tumors using multimodal profiling from 32,000+ specimens.
- Why it matters: Patient selection is becoming the main bottleneck as antibody therapies expand, requiring reliable ways to identify which tumors express the right targets and in what immune context.
- What they did: The team integrated transcriptomic, proteomic, spatial, and single-cell data from 32,000+ specimens to quantify prevalence, intratumoral heterogeneity, immune contexture, internalization, and payload-sensitivity, then built ANCHOR and ReSort.
- The result: ReSort supports virtual basket and umbrella trial matching, shows concordance with clinical assays, predicts therapeutic response in patient-derived models, and enables repurposing opportunities in rare malignancies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.